François Ferré is the co-CEO of ALMA LifeSciences LLC, a healthcare investment and consulting firm with a focus on prevention. He was the Chairman and co-Founder of AltheaDx, a precision medicine company until March 2022 when it was acquired by Castle Biosciences. Dr. Ferre was the CEO of AltheaDx from 2010 to June 2013.

Prior to AltheaDx, Dr. Ferré co-founded Althea Technologies and served as co-CEO from 1998 until 2008. Althea was successfully acquired by Ajinomoto in 2013. He was a Director of Althea Technologies until April 2013 and was a Director of Ajinomoto-Althea until 2019. He also currently serves on the board of a number of additional private companies such as Agendia and Neuralace. He is a Managing Director of Mesa Verde Venture Partners and he is a Board member of La Jolla Institute of Allergy and Immunology.

Dr. Ferré was the winner of the 2005 E&Y Entrepreneur of the Year award in the Life Sciences category. Dr. Ferré is a leader in gene quantification and biomarker development and published several authoritative reviews on these topics, including the co-edition of a bestseller book on PCR with Nobel Prize winner, Dr. Kary Mullis. He received his PhD in molecular oncology from the Pasteur Institute, France and did his post-doctoral training at the University of California, San Diego.